お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
922435

米国の末梢血管装置市場(2020年~2026年): MedSuite

Peripheral Vascular Devices Market Report Suite | United States | 2020-2026 | MedSuite

出版日: | 発行: iData Research Inc. | ページ情報: 英文 997 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.83円

※ Single Userライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。
認証されたPC上のみでの閲覧となっております。

米国の末梢血管装置市場(2020年~2026年): MedSuite
出版日: 2020年01月13日
発行: iData Research Inc.
ページ情報: 英文 997 Pages
納期: 即日から翌営業日
担当者のコメント
当サービス(MedSuite)は、セグメント別(MedCore)にご注文可能です。(USD3,995/1セグメント)。まずはサンプル送付させていただきますので、ご希望のセグメントをお知らせください。
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、米国における末梢血管装置市場について調査し、市場の動向、疾患の概要、疾患・製品タイプ別による分析と予測、成長促進要因・成長抑制要因、競合状況、手術件数など、体系的な情報を提供しています。

目次

エグゼクティブサマリー

米国の末梢血管デバイス市場の概要

競合分析

市場動向

調査方法

市場開発

手術件数

調査対象の手術コード

対象市場

主要レポートのアップデート

バージョン履歴

調査方法

疾患概要

  • 基本解剖学
  • 疾患の治療と診断
    • 大動脈瘤
    • アテローム性動脈硬化
    • 末梢動脈疾患(PAD)
    • 深部静脈血栓症(DVT)
    • 肺塞栓症(PE)
  • 患者統計
    • 大動脈瘤
    • アテローム性動脈硬化
    • 末梢動脈疾患(PAD)
    • 深部静脈血栓症(DVT)
    • 肺塞栓症(PE)

製品評価

  • イントロダクション
  • 製品ポートフォリオ
    • 末梢血管ステント
    • 静脈ステント
    • 経皮的血管形成術(PTA)バルーン
    • 薬剤コーテッドバルーン (DCB)
    • アテレクトミーデバイス
    • 慢性完全閉塞病変(CTO)デバイス
    • 血管内砕石術
    • 外科移植
    • ステントグラフト
    • 塞栓防止装置
    • 周辺血栓管理デバイス
    • 下大静脈フィルター
    • 頸動脈シャント
    • 診断・インターベンショナルカテーテル
    • 診断・インターベンショナルガイドワイヤー
    • イントロデューサーシース
    • 血管閉鎖デバイス(VCD)
    • 経カテーテル塞栓装置
    • 末梢IVUS (血管内超音波) カテーテル
  • 規制上の問題・リコール
    • Abbott
    • Argon Medical
    • Arrow International
    • Atrium Medical
    • BD
    • Boston Scientific
    • Cardinal Health
    • Cardiovascular System (C.S.I.)
    • Cook Medical
    • Cordis (Cardinal Health)
    • Endologix
    • Edwards Lifesciences
    • Maquet
    • Medtronic
    • Spectranetics (Philips)
    • Shockwave Medical, Inc.
    • テルモ
    • その他の企業
  • 臨床試験
      Abbott
    • B. Braun
    • Boston Scientific
    • C.R. Bard (BD)
    • Cardinal Health
    • Cook Medical
    • Cordis (Cardinal Health)
    • Medtronic
    • Merit Medical
    • Philips/Spectranetics
    • Shockwave Medical, Inc.
    • Surmodics
    • Terumo
    • W.L. Gore
    • その他の企業

米国の末梢血管デバイス市場の概要

  • イントロダクション
    • アテローム性動脈硬化
    • 末梢動脈疾患(PAD)
  • 市場概要
  • 動向分析:セグメント別
  • 成長促進要因・抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 競合市場シェア分析
  • 合併と買収
  • 企業プロファイル
    • Abbott
    • Becton Dickinson (BD)
    • Boston Scientific
    • Cardinal Health
    • Cook Medical
    • Maquet
    • Medtronic
    • Teleflex
    • Terumo Interventional System (TIS)
    • W.L. Gore
  • SWOT分析
    • Abbott
    • B. Braun
    • Boston Scientific
    • BD
    • Cardinal Health
    • Cook Medical
    • Integra Lifesciences
    • Maquet
    • Medtronic
    • Merit Medical
    • Phillips
    • Teleflex
    • Terumo
    • W.L. Gore

手術件数

  • イントロダクション
  • 手術件数
    • 末梢血管手術件数
    • 末梢血管手術件数:デバイスの種類、適応症、介入、医療環境別
    • 末梢血管ステント処置件数
    • 末梢静脈ステント処置件数
    • PTAバルーンカテーテル処置件数
    • 薬剤コーテッドバルーン処置件数
    • アテレクトミー処置件数
図表

LIST OF CHARTS

  • Chart 1 1: Peripheral Vascular Device Market by Segment, U.S., 2016 - 2026 3
  • Chart 1 2: Peripheral Vascular Device Market Overview, U.S., 2019 & 2026 3
  • Chart 4 1: Peripheral Vascular Device Market by Segment, U.S., 2016 - 2026 189
  • Chart 4 2: Peripheral Vascular Device Market Breakdown, U.S., 2019 190
  • Chart 4 3: Peripheral Vascular Device Market Breakdown, U.S., 2026 191
  • Chart 4 4: Growth Rates by Segment, Peripheral Vascular Device Market, U.S., 2017 - 2026 196
  • Chart 4 5: Leading Competitors, Peripheral Vascular Device Market, U.S., 2020 217
  • Chart 5 1: Peripheral Vascular Procedures by Type, U.S., 2016 - 2026 255
  • Chart 5 2: Stenting Procedures by Stent Type, U.S., 2016 - 2026 287
  • Chart 5 3: Bare-Metal Stent Procedures by Delivery Method, U.S., 2016 - 2026 289
  • Chart 5 4: Bare-Metal Stent Procedures by Indication, U.S., 2016 - 2026 292
  • Chart 5 5: Covered Stent Procedures by Indication, U.S., 2016 - 2026 294
  • Chart 5 6: Drug-Eluting Stent Procedures by Indication, U.S., 2016 - 2026 296
  • Chart 5 7: Peripheral Venous Stent Procedures, U.S., 2016 - 2026 299
  • Chart 5 8: PTA Balloon Catheter Procedures, U.S., 2016 - 2026 302
  • Chart 5 9: Drug-Coated Balloon Procedures by Indication, U.S., 2016 - 2026 306
  • Chart 5 10: Drug-Coated Balloon Procedures by Care Setting, U.S., 2016 - 2026 308
  • Chart 5 11: Atherectomy Procedures by Device Type, U.S., 2016 - 2026 312
  • Chart 5 12: Atherectomy Procedures by Indication, U.S., 2016 - 2026 315
  • Chart 5 13: Fem-Popliteal Artery Atherectomy Procedures by Type, U.S., 2016 - 2026 317
  • Chart 5 14: Infra-Popliteal Artery Atherectomy Procedures by Type, U.S., 2016 - 2026 319
  • Chart 5 15: Intravascular Lithotripsy Procedures by Indication, U.S., 2016 - 2026 322
  • Chart 5 16: CTO Device Procedures by Type, U.S., 2016 - 2026 325
  • Chart 5 17: Surgical Graft Procedures by Graft Material, U.S., 2016 - 2026 328
  • Chart 5 18: Surgical Graft Procedures by Indication, U.S., 2016 - 2026 330
  • Chart 5 19: Lower Limb Surgical Graft Procedures by Anatomy, U.S., 2016 - 2026 332
  • Chart 5 20: Aorta Repair Surgical Graft Procedures by Anatomy, U.S., 2016 - 2026 334
  • Chart 5 21: Endovascular Stent Graft Procedures by Type, U.S., 2016 - 2026 337
  • Chart 5 22: EVAR Procedures by Anatomy, U.S., 2019 339
  • Chart 5 23: EVAR Procedures by Complexity, U.S., 2016 - 2026 341
  • Chart 5 24: EVAR Procedures by Fenestration, U.S., 2016 - 2026 343
  • Chart 5 25: EVAR Procedures by Anesthesia Type, U.S., 2016 - 2026 345
  • Chart 5 26: EVAR Procedures by Gender, U.S., 2016 - 2026 347
  • Chart 5 27: TEVAR Procedures by Indication, U.S., 2019 349
  • Chart 5 28: TEVAR Procedures by Gender, U.S., 2016 - 2026 351
  • Chart 5 29: Embolic Protection Procedures by Type, U.S., 2016 - 2026 354
  • Chart 5 30: Peripheral Thrombus Management Procedures by Procedure Type, U.S., 2016 - 2026 358
  • Chart 5 31: Peripheral Thrombus Management Procedures by Indication, U.S., 2016 - 2026 360
  • Chart 5 32: Inferior Vena Cava Filter Procedures by Procedure Type, U.S., 2016 - 2026 364
  • Chart 5 33: Transcarotid Artery Revascularization Procedures, U.S., 2016 - 2026 368
  • Chart 5 34: Vascular Closure Procedures by Device Type, U.S., 2016 - 2026 371
  • Chart 5 35: Invasive Vascular Closure Procedures by Device Size, U.S., 2016 - 2026 373
  • Chart 5 36: Vascular Closure Procedures by Approach, U.S., 2016 - 2026 375
  • Chart 5 37: Transcatheter Embolization Procedures by Device Type, U.S., 2016 - 2026 379
  • Chart 5 38: Transcatheter Particle Embolization Procedures by Device Type, U.S., 2016 - 2026 381
  • Chart 5 39: Transcatheter Coil Embolization Procedures by Device Type, U.S., 2016 - 2026 383
  • Chart 5 40: Peripheral IVUS Procedures by Indication, U.S., 2016 - 2026 386
  • Chart 6 1: Peripheral Vascular Stent Market by Segment, U.S., 2016 - 2026 395
  • Chart 6 2: Peripheral Vascular Stent Market Breakdown, U.S., 2019 396
  • Chart 6 3: Peripheral Vascular Stent Market Breakdown, U.S., 2026 397
  • Chart 6 4: Total Bare-Metal Peripheral Arterial Stent Market, U.S., 2016 - 2026 401
  • Chart 6 5: Bare-Metal Stent Market by Indication, U.S., 2016 - 2026 405
  • Chart 6 6: Bare-Metal Carotid Stent Market, U.S., 2016 - 2026 407
  • Chart 6 7: Bare-Metal Renal Stent Market, U.S., 2016 - 2026 409
  • Chart 6 8: Bare-Metal Iliac Stent Market, U.S., 2016 - 2026 411
  • Chart 6 9: Bare-Metal Fem-Popliteal Stent Market, U.S., 2016 - 2026 413
  • Chart 6 10: Bare-Metal Infra-Popliteal Stent Market, U.S., 2016 - 2026 415
  • Chart 6 11: Bare-Metal Stent Market by Delivery Platform, U.S., 2016 - 2026 417
  • Chart 6 12: Self-Expanding Bare-Metal Stent Market, U.S., 2016 - 2026 419
  • Chart 6 13: Balloon-Expanding Bare-Metal Stent Market, U.S., 2016 - 2026 421
  • Chart 6 14: Covered Stent Market by Segment, U.S., 2016 - 2026 424
  • Chart 6 15: Total Covered Stent Market, U.S., 2016 - 2026 426
  • Chart 6 16: Iliac Covered Stent Market, U.S., 2016 - 2026 428
  • Chart 6 17: Fem- Popliteal Covered Stent Market, U.S., 2016 - 2026 430
  • Chart 6 18: AV Access Covered Stent Market, U.S., 2016 - 2026 432
  • Chart 6 19: Drug-Eluting Stent Market by Segment, U.S., 2016 - 2026 435
  • Chart 6 20: Total Drug-Eluting Stent Market, U.S., 2016 - 2026 437
  • Chart 6 21: SFA Drug-Eluting Stent Market, U.S., 2016 - 2026 439
  • Chart 6 22: Infra-Popliteal Drug-Eluting Stent Market, U.S., 2016 - 2026 441
  • Chart 6 23: Units Sold by Stent Length, Bare-Metal Carotid Stent Market, U.S., 2016 - 2026 445
  • Chart 6 24: Units Sold by Stent Length, Bare-Metal Renal Stent Market, U.S., 2016 - 2026 447
  • Chart 6 25: Units Sold by Stent Length, Bare-Metal Iliac Stent Market, U.S., 2016 - 2026 449
  • Chart 6 26: Units Sold by Stent Length, Bare-Metal Fem-Popliteal Stent Market, U.S., 2016 - 2026 451
  • Chart 6 27: Leading Competitors, Peripheral Vascular Stent Market, U.S., 2019 461
  • Chart 6 28: Leading Competitors, Bare-Metal Stent Market, U.S., 2019 466
  • Chart 6 29: Leading Competitors, Bare-Metal Stent Market by Delivery Platform, U.S., 2019 468
  • Chart 6 30: Leading Competitors, Bare-Metal Stent Market by Delivery Platform, U.S., 2019 470
  • Chart 6 31: Leading Competitors, Drug-Eluting Stent Market by Indication, U.S., 2019 473
  • Chart 7 1: Venous Stent Market, U.S., 2016 - 2026 478
  • Chart 7 2: Leading Competitors, Venous Stent Market, U.S., 2019 487
  • Chart 8 1: PTA Balloon Catheter Market by Segment, U.S., 2016 - 2026 492
  • Chart 8 2: PTA Balloon Catheter Market Breakdown, U.S., 2019 493
  • Chart 8 3: PTA Balloon Catheter Market Breakdown, U.S., 2026 494
  • Chart 8 4: Total PTA Balloon Catheter Market, U.S., 2016 - 2026 497
  • Chart 8 5: Standard PTA Balloon Catheter Market by Segment, U.S., 2016 - 2026 499
  • Chart 8 6: Total Standard PTA Balloon Catheter Market, U.S., 2016 - 2026 501
  • Chart 8 7: Hospital Standard PTA Balloon Catheter Market, U.S., 2016 - 2026 503
  • Chart 8 8: Office-Based Lab Standard PTA Balloon Catheter Market, U.S., 2016 - 2026 505
  • Chart 8 9: High-Pressure PTA Balloon Catheter Market, U.S., 2016 - 2026 507
  • Chart 8 10: Large PTA Balloon Catheter Market, U.S., 2016 - 2026 509
  • Chart 8 11: Small PTA Balloon Catheter Market by Segment, U.S., 2016 - 2026 512
  • Chart 8 12: Total Small PTA Balloon Catheter Market, U.S., 2016 - 2026 514
  • Chart 8 13: 0.014" Small PTA Balloon Catheter Market, U.S., 2016 - 2026 516
  • Chart 8 14: 0.018" Small PTA Balloon Catheter Market, U.S., 2016 - 2026 518
  • Chart 8 15: Specialty PTA Balloon Catheter Market, U.S., 2016 - 2026 521
  • Chart 8 16: Units Sold by Application, PTA Balloon Catheter Market, U.S., 2016 - 2026 524
  • Chart 8 17: Leading Competitors, PTA Balloon Market, U.S., 2019 537
  • Chart 9 1: Drug-Coated Balloon Market by Segment, U.S., 2016 - 2026 542
  • Chart 9 2: Drug-Coated Balloon Market Breakdown, U.S., 2019 543
  • Chart 9 3: Drug-Coated Balloon Market Breakdown, U.S., 2026 544
  • Chart 9 4: SFA DCB Market, U.S., 2016 - 2026 547
  • Chart 9 5: BTK DCB Market, U.S., 2016 - 2026 549
  • Chart 9 6: AV Access DCB Market, U.S., 2016 - 2026 551
  • Chart 9 7: Units Sold by Sheath Size, Drug-Coated Balloon Market, U.S., 2016 - 2026 554
  • Chart 9 8: Units Sold by Balloon Diameter, Drug-Coated Balloon Market, U.S., 2016 - 2026 556
  • Chart 9 9: Units Sold by Balloon Length, Drug-Coated Balloon Market, U.S., 2016 - 2026 558
  • Chart 9 10: Units Sold by Shaft Length, Drug-Coated Balloon Market, U.S., 2016 - 2026 560
  • Chart 9 11: Units Sold by Rated Burst Pressure, Drug-Coated Balloon Market, U.S., 2016 - 2026 562
  • Chart 9 12: Units Sold by Care Setting, Drug-Coated Balloon Market, U.S., 2016 - 2026 564
  • Chart 9 13: Leading Competitors, Drug-Coated Balloon Market, U.S., 2019 571
  • Chart 10 1: Atherectomy Device Market by Segment, U.S., 2016 - 2026 576
  • Chart 10 2: Atherectomy Device Market Breakdown by Segment, U.S., 2019 577
  • Chart 10 3: Atherectomy Device Market Breakdown by Segment, U.S., 2026 578
  • Chart 10 4: Laser Atherectomy Device Market by Segment, U.S., 2016 - 2026 581
  • Chart 10 5: Laser Atherectomy Console Market, U.S., 2016 - 2026 584
  • Chart 10 6: Laser Atherectomy Disposable Market, U.S., 2016 - 2026 586
  • Chart 10 7: Mechanical Atherectomy Disposable Market, U.S., 2016 - 2026 588
  • Chart 10 8: Atherectomy Disposables Market by Setting, U.S., 2016 - 2026 590
  • Chart 10 9: Hospital Atherectomy Disposables Market, U.S., 2016 - 2026 592
  • Chart 10 10: Office-Based Lab Atherectomy Disposables Market, U.S., 2016 - 2026 594
  • Chart 10 11: Leading Competitors, Atherectomy Device Market, U.S., 2019 604
  • Chart 11 1: Intravascular Lithotripsy Market, U.S., 2016 - 2026 608
  • Chart 11 2: Intravascular Lithotripsy Units Sold by Diameter, U.S., 2019 610
  • Chart 12 1: CTO Device Market by Segment, U.S., 2016 - 2026 616
  • Chart 12 2: CTO Device Market Breakdown, U.S., 2019 617
  • Chart 12 3: CTO Device Market Breakdown, U.S., 2026 618
  • Chart 12 4: Total CTO Device Market, U.S., 2016 - 2026 620
  • Chart 12 5: Re-Entry Device Market, U.S., 2016 - 2026 622
  • Chart 12 6: Re-Canalization Device Market, U.S., 2016 - 2026 625
  • Chart 12 7: Leading Competitors, CTO Device Market, U.S., 2019 631
  • Chart 13 1: Surgical Graft Market by Indication, U.S., 2016 - 2026 636
  • Chart 13 2: Surgical Graft Market Breakdown by Indication, U.S., 2019 637
  • Chart 13 3: Surgical Graft Market Breakdown by Indication, U.S., 2026 638
  • Chart 13 4: Surgical Graft Market by Material, U.S., 2016 - 2026 640
  • Chart 13 5: Surgical Graft Market Breakdown by Material, U.S., 2019 641
  • Chart 13 6: Surgical Graft Market Breakdown by Material, U.S., 2026 642
  • Chart 13 7: Total Surgical Graft Market, U.S., 2016 - 2026 645
  • Chart 13 8: Lower Limb Surgical Graft Market by Segment, U.S., 2016 - 2026 647
  • Chart 13 9: Total Lower Limb Surgical Graft Market, U.S., 2016 - 2026 649
  • Chart 13 10: Above-the-Knee Surgical Graft Market, U.S., 2016 - 2026 651
  • Chart 13 11: Below-the-Knee Surgical Graft Market, U.S., 2016 - 2026 653
  • Chart 13 12: Aorta Repair Surgical Graft Market by Segment, U.S., 2016 - 2026 656
  • Chart 13 13: Total Aorta Repair Surgical Graft Market, U.S., 2016 - 2026 658
  • Chart 13 14: Abdominal Aortic Surgical Graft Market, U.S., 2016 - 2026 660
  • Chart 13 15: Thoracic Aortic Surgical Graft Market, U.S., 2016 - 2026 662
  • Chart 13 16: Extra-Anatomical Bypass Surgical Graft Market, U.S., 2016 - 2026 664
  • Chart 13 17: Polyester Surgical Graft Market, U.S., 2016 - 2026 666
  • Chart 13 18: ePTFE Surgical Graft Market, U.S., 2016 - 2026 668
  • Chart 13 19: Leading Competitors, Surgical Graft Market, U.S., 2019 675
  • Chart 14 1: Stent Graft Market by Segment, U.S., 2016 - 2026 678
  • Chart 14 2: Stent Graft Market Breakdown, U.S., 2019 679
  • Chart 14 3: Stent Graft Market Breakdown, U.S., 2026 680
  • Chart 14 4: Total Stent Graft Market, U.S., 2016 - 2026 682
  • Chart 14 5: AAA Stent Graft Market by Segment, U.S., 2016 - 2026 685
  • Chart 14 6: Total AAA Stent Graft Market, U.S., 2016 - 2026 687
  • Chart 14 7: Bifurcated Main Body Graft Market, U.S., 2016 - 2026 689
  • Chart 1 1: Peripheral Vascular Device Market by Segment, U.S., 2016 - 2026 3
  • Chart 1 2: Peripheral Vascular Device Market Overview, U.S., 2019 & 2026 3
  • Chart 4 1: Peripheral Vascular Device Market by Segment, U.S., 2016 - 2026 189
  • Chart 4 2: Peripheral Vascular Device Market Breakdown, U.S., 2019 190
  • Chart 4 3: Peripheral Vascular Device Market Breakdown, U.S., 2026 191
  • Chart 4 4: Growth Rates by Segment, Peripheral Vascular Device Market, U.S., 2017 - 2026 196
  • Chart 4 5: Leading Competitors, Peripheral Vascular Device Market, U.S., 2020 217
  • Chart 5 1: Peripheral Vascular Procedures by Type, U.S., 2016 - 2026 255
  • Chart 5 2: Stenting Procedures by Stent Type, U.S., 2016 - 2026 287
  • Chart 5 3: Bare-Metal Stent Procedures by Delivery Method, U.S., 2016 - 2026 289
  • Chart 5 4: Bare-Metal Stent Procedures by Indication, U.S., 2016 - 2026 292
  • Chart 5 5: Covered Stent Procedures by Indication, U.S., 2016 - 2026 294
  • Chart 5 6: Drug-Eluting Stent Procedures by Indication, U.S., 2016 - 2026 296
  • Chart 5 7: Peripheral Venous Stent Procedures, U.S., 2016 - 2026 299
  • Chart 5 8: PTA Balloon Catheter Procedures, U.S., 2016 - 2026 302
  • Chart 5 9: Drug-Coated Balloon Procedures by Indication, U.S., 2016 - 2026 306
  • Chart 5 10: Drug-Coated Balloon Procedures by Care Setting, U.S., 2016 - 2026 308
  • Chart 5 11: Atherectomy Procedures by Device Type, U.S., 2016 - 2026 312
  • Chart 5 12: Atherectomy Procedures by Indication, U.S., 2016 - 2026 315
  • Chart 5 13: Fem-Popliteal Artery Atherectomy Procedures by Type, U.S., 2016 - 2026 317
  • Chart 5 14: Infra-Popliteal Artery Atherectomy Procedures by Type, U.S., 2016 - 2026 319
  • Chart 5 15: Intravascular Lithotripsy Procedures by Indication, U.S., 2016 - 2026 322
  • Chart 5 16: CTO Device Procedures by Type, U.S., 2016 - 2026 325
  • Chart 5 17: Surgical Graft Procedures by Graft Material, U.S., 2016 - 2026 328
  • Chart 5 18: Surgical Graft Procedures by Indication, U.S., 2016 - 2026 330
  • Chart 5 19: Lower Limb Surgical Graft Procedures by Anatomy, U.S., 2016 - 2026 332
  • Chart 5 20: Aorta Repair Surgical Graft Procedures by Anatomy, U.S., 2016 - 2026 334
  • Chart 5 21: Endovascular Stent Graft Procedures by Type, U.S., 2016 - 2026 337
  • Chart 5 22: EVAR Procedures by Anatomy, U.S., 2019 339
  • Chart 5 23: EVAR Procedures by Complexity, U.S., 2016 - 2026 341
  • Chart 5 24: EVAR Procedures by Fenestration, U.S., 2016 - 2026 343
  • Chart 5 25: EVAR Procedures by Anesthesia Type, U.S., 2016 - 2026 345
  • Chart 5 26: EVAR Procedures by Gender, U.S., 2016 - 2026 347
  • Chart 5 27: TEVAR Procedures by Indication, U.S., 2019 349
  • Chart 5 28: TEVAR Procedures by Gender, U.S., 2016 - 2026 351
  • Chart 5 29: Embolic Protection Procedures by Type, U.S., 2016 - 2026 354
  • Chart 5 30: Peripheral Thrombus Management Procedures by Procedure Type, U.S., 2016 - 2026 358
  • Chart 5 31: Peripheral Thrombus Management Procedures by Indication, U.S., 2016 - 2026 360
  • Chart 5 32: Inferior Vena Cava Filter Procedures by Procedure Type, U.S., 2016 - 2026 364
  • Chart 5 33: Transcarotid Artery Revascularization Procedures, U.S., 2016 - 2026 368
  • Chart 5 34: Vascular Closure Procedures by Device Type, U.S., 2016 - 2026 371
  • Chart 5 35: Invasive Vascular Closure Procedures by Device Size, U.S., 2016 - 2026 373
  • Chart 5 36: Vascular Closure Procedures by Approach, U.S., 2016 - 2026 375
  • Chart 5 37: Transcatheter Embolization Procedures by Device Type, U.S., 2016 - 2026 379
  • Chart 5 38: Transcatheter Particle Embolization Procedures by Device Type, U.S., 2016 - 2026 381
  • Chart 5 39: Transcatheter Coil Embolization Procedures by Device Type, U.S., 2016 - 2026 383
  • Chart 5 40: Peripheral IVUS Procedures by Indication, U.S., 2016 - 2026 386
  • Chart 6 1: Peripheral Vascular Stent Market by Segment, U.S., 2016 - 2026 395
  • Chart 6 2: Peripheral Vascular Stent Market Breakdown, U.S., 2019 396
  • Chart 6 3: Peripheral Vascular Stent Market Breakdown, U.S., 2026 397
  • Chart 6 4: Total Bare-Metal Peripheral Arterial Stent Market, U.S., 2016 - 2026 401
  • Chart 6 5: Bare-Metal Stent Market by Indication, U.S., 2016 - 2026 405
  • Chart 6 6: Bare-Metal Carotid Stent Market, U.S., 2016 - 2026 407
  • Chart 6 7: Bare-Metal Renal Stent Market, U.S., 2016 - 2026 409
  • Chart 6 8: Bare-Metal Iliac Stent Market, U.S., 2016 - 2026 411
  • Chart 6 9: Bare-Metal Fem-Popliteal Stent Market, U.S., 2016 - 2026 413
  • Chart 6 10: Bare-Metal Infra-Popliteal Stent Market, U.S., 2016 - 2026 415
  • Chart 6 11: Bare-Metal Stent Market by Delivery Platform, U.S., 2016 - 2026 417
  • Chart 6 12: Self-Expanding Bare-Metal Stent Market, U.S., 2016 - 2026 419
  • Chart 6 13: Balloon-Expanding Bare-Metal Stent Market, U.S., 2016 - 2026 421
  • Chart 6 14: Covered Stent Market by Segment, U.S., 2016 - 2026 424
  • Chart 6 15: Total Covered Stent Market, U.S., 2016 - 2026 426
  • Chart 6 16: Iliac Covered Stent Market, U.S., 2016 - 2026 428
  • Chart 6 17: Fem- Popliteal Covered Stent Market, U.S., 2016 - 2026 430
  • Chart 6 18: AV Access Covered Stent Market, U.S., 2016 - 2026 432
  • Chart 6 19: Drug-Eluting Stent Market by Segment, U.S., 2016 - 2026 435
  • Chart 6 20: Total Drug-Eluting Stent Market, U.S., 2016 - 2026 437
  • Chart 6 21: SFA Drug-Eluting Stent Market, U.S., 2016 - 2026 439
  • Chart 6 22: Infra-Popliteal Drug-Eluting Stent Market, U.S., 2016 - 2026 441
  • Chart 6 23: Units Sold by Stent Length, Bare-Metal Carotid Stent Market, U.S., 2016 - 2026 445
  • Chart 6 24: Units Sold by Stent Length, Bare-Metal Renal Stent Market, U.S., 2016 - 2026 447
  • Chart 6 25: Units Sold by Stent Length, Bare-Metal Iliac Stent Market, U.S., 2016 - 2026 449
  • Chart 6 26: Units Sold by Stent Length, Bare-Metal Fem-Popliteal Stent Market, U.S., 2016 - 2026 451
  • Chart 6 27: Leading Competitors, Peripheral Vascular Stent Market, U.S., 2019 461
  • Chart 6 28: Leading Competitors, Bare-Metal Stent Market, U.S., 2019 466
  • Chart 6 29: Leading Competitors, Bare-Metal Stent Market by Delivery Platform, U.S., 2019 468
  • Chart 6 30: Leading Competitors, Bare-Metal Stent Market by Delivery Platform, U.S., 2019 470
  • Chart 6 31: Leading Competitors, Drug-Eluting Stent Market by Indication, U.S., 2019 473
  • Chart 7 1: Venous Stent Market, U.S., 2016 - 2026 478
  • Chart 7 2: Leading Competitors, Venous Stent Market, U.S., 2019 487
  • Chart 8 1: PTA Balloon Catheter Market by Segment, U.S., 2016 - 2026 492
  • Chart 8 2: PTA Balloon Catheter Market Breakdown, U.S., 2019 493
  • Chart 8 3: PTA Balloon Catheter Market Breakdown, U.S., 2026 494
  • Chart 8 4: Total PTA Balloon Catheter Market, U.S., 2016 - 2026 497
  • Chart 8 5: Standard PTA Balloon Catheter Market by Segment, U.S., 2016 - 2026 499
  • Chart 8 6: Total Standard PTA Balloon Catheter Market, U.S., 2016 - 2026 501
  • Chart 8 7: Hospital Standard PTA Balloon Catheter Market, U.S., 2016 - 2026 503
  • Chart 8 8: Office-Based Lab Standard PTA Balloon Catheter Market, U.S., 2016 - 2026 505
  • Chart 8 9: High-Pressure PTA Balloon Catheter Market, U.S., 2016 - 2026 507
  • Chart 8 10: Large PTA Balloon Catheter Market, U.S., 2016 - 2026 509
  • Chart 8 11: Small PTA Balloon Catheter Market by Segment, U.S., 2016 - 2026 512
  • Chart 8 12: Total Small PTA Balloon Catheter Market, U.S., 2016 - 2026 514
  • Chart 8 13: 0.014" Small PTA Balloon Catheter Market, U.S., 2016 - 2026 516
  • Chart 8 14: 0.018" Small PTA Balloon Catheter Market, U.S., 2016 - 2026 518
  • Chart 8 15: Specialty PTA Balloon Catheter Market, U.S., 2016 - 2026 521
  • Chart 8 16: Units Sold by Application, PTA Balloon Catheter Market, U.S., 2016 - 2026 524
  • Chart 8 17: Leading Competitors, PTA Balloon Market, U.S., 2019 537

For a full Table of Contents, please contact iData

LIST OF FIGURES

  • Figure 1 1: Peripheral Vascular Device Market Share Ranking by Segment, U.S., 2019 (1 of 4) 5
  • Figure 1 2: Peripheral Vascular Device Market Share Ranking by Segment, U.S., 2019 (2 of 4) 5
  • Figure 1 3: Peripheral Vascular Device Market Share Ranking by Segment, U.S., 2019 (3 of 4) 5
  • Figure 1 4: Peripheral Vascular Device Market Share Ranking by Segment, U.S., 2019 (4 of 4) 6
  • Figure 1 5: Companies Researched in this Report, U.S., 2019 (1 of 2) 7
  • Figure 1 6: Companies Researched in this Report, U.S., 2019 (2 of 2) 8
  • Figure 1 7: Factors Impacting the Peripheral Vascular Device Market by Segment, U.S. (1 of 3) 9
  • Figure 1 8: Factors Impacting the Peripheral Vascular Device Market by Segment, U.S. (2 of 3) 10
  • Figure 1 9: Factors Impacting the Peripheral Vascular Device Market by Segment, U.S. (3 of 3) 11
  • Figure 1 10: Recent Events in the Peripheral Vascular Market, U.S., 2016 - 2019 12
  • Figure 1 11: Peripheral Vascular Procedures Covered by Indication, Intervention & Care Setting, U.S. (1 of 3) 13
  • Figure 1 12: Peripheral Vascular Procedures Covered by Indication, Intervention & Care Setting, U.S. (2 of 3) 14
  • Figure 1 13: Peripheral Vascular Procedures Covered by Indication, Intervention & Care Setting, U.S. (3 of 3) 15
  • Figure 1 14: Peripheral Vascular Procedures Covered, U.S. (1 of 5) 16
  • Figure 1 15: Peripheral Vascular Procedures Covered, U.S. (2 of 5) 17
  • Figure 1 16: Peripheral Vascular Procedures Covered, U.S. (3 of 5) 18
  • Figure 1 17: Peripheral Vascular Procedures Covered, U.S. (4 of 5) 19
  • Figure 1 18: Peripheral Vascular Procedures Covered, U.S. (5 of 5) 20
  • Figure 1 19: Procedure Codes Investigated, U.S. 21
  • Figure 1 20: Peripheral Vascular Device Markets Covered, U.S. (1 of 8) 22
  • Figure 1 21: Peripheral Vascular Device Markets Covered, U.S. (2 of 8) 23
  • Figure 1 22: Peripheral Vascular Device Markets Covered, U.S. (3 of 8) 24
  • Figure 1 23: Peripheral Vascular Device Markets Covered, U.S. (4 of 8) 25
  • Figure 1 24: Peripheral Vascular Device Markets Covered, U.S. (5 of 8) 26
  • Figure 1 25: Peripheral Vascular Device Markets Covered, U.S. (6 of 8) 27
  • Figure 1 26: Peripheral Vascular Device Markets Covered, U.S. (7 of 8) 28
  • Figure 1 27: Peripheral Vascular Device Markets Covered, U.S. (8 of 8) 29
  • Figure 1 28: Key Report Updates 30
  • Figure 1 29: Version History 31
  • Figure 3 1: Peripheral Vascular Stent by Company (1 of 2) 56
  • Figure 3 2: Peripheral Vascular Stent by Company (2 of 2) 57
  • Figure 3 3: Venous Stent by Company 58
  • Figure 3 4: PTA Balloon Catheter by Company (1 of 3) 60
  • Figure 3 5: PTA Balloon Catheter by Company (2 of 3) 61
  • Figure 3 6: PTA Balloon Catheter by Company (3 of 3) 62
  • Figure 3 7: Drug-Coated Balloon by Company 64
  • Figure 3 8: Atherectomy Device by Company 66
  • Figure 3 9: Chronic Total Occlusion Device by Company 68
  • Figure 3 10: Lithotripsy Device by Company 69
  • Figure 3 11: Surgical Graft by Company (1 of 2) 71
  • Figure 3 12: Surgical Graft by Company (2 of 2) 72
  • Figure 3 13: Stent Graft by Company 74
  • Figure 3 14: Embolic Protection Device by Company 76
  • Figure 3 15: Peripheral Thrombus Management by Company 79
  • Figure 3 16: Inferior Vena Cava Filter by Company 80
  • Figure 3 17: Carotid Shunt by Company 81
  • Figure 3 18: Diagnostic and Interventional Catheters by Company (1 of 2) 83
  • Figure 3 19: Diagnostic and Interventional Catheters by Company (2 of 2) 84
  • Figure 3 20: Diagnostic and Interventional Guidewire by Company (1 of 3) 86
  • Figure 3 21: Diagnostic and Interventional Guidewire by Company (2 of 3) 87
  • Figure 3 22: Diagnostic and Interventional Guidewire by Company (3 of 3) 88
  • Figure 3 23: Introducer Sheath by Company (1 of 4) 89
  • Figure 3 24: Introducer Sheath by Company (2 of 4) 90
  • Figure 3 25: Introducer Sheath by Company (3 of 4) 91
  • Figure 3 26: Introducer Sheath by Company (4 of 4) 92
  • Figure 3 27: Vascular Closure Device by Company (1 of 2) 93
  • Figure 3 28: Vascular Closure Device by Company (2 of 2) 94
  • Figure 3 29: Transcatheter Embolization Devices by Company (1 of 2) 96
  • Figure 3 30: Transcatheter Embolization Devices by Company (2 of 2) 97
  • Figure 3 31: Peripheral IVUS Catheter by Company 98
  • Figure 3 32: Class 2 Device Recall RX ACCULINK Carotid Stent System 99
  • Figure 3 33: Class 2 Device Recall StarClose SE Vascular Closure System, Abbot 99
  • Figure 3 34: Class 2 Device Recall ClosureFast Micro Introducer Sheath Set, Argon Medical 100
  • Figure 3 35: Class 2 Device Recall Super ArrowFlex Percutaneous Sheath Introducer Sets, Arrow 100
  • Figure 3 36: Class 2 Device Recall Percutaneous Sheath Introducer Kit, Arrow 101
  • Figure 3 37: Class 2 Device Recall Super ArrowFlex(R) Percutaneous Sheath Introducer Set with Integral Hemostasis Valve/Side Port, Arrow 101
  • Figure 3 38: Class 2 Device Recall Arrow 101
  • Figure 3 39: Class 2 Device Recall Arrow Percutaneous Sheath Introducer Kits, Arrow 102
  • Figure 3 40: Class 2 Device Recall iCAST and Advanta 103
  • Figure 3 41: Class 2 Device Recall Denali Filter Femoral Delivery System, Bard Peripheral Vascular Inc 104
  • Figure 3 42: Class 2 Device Recall Denali Filter Jugular Subclavian Delivery System, Bard Peripheral Vascular Inc 104
  • Figure 3 43: Class 1 Device Recall Bard Peripheral Vascular 104
  • Figure 3 44: Class 2 Device Recall FLAIR Endovascular Stent Graft, Bard Peripheral Vascular Inc 105
  • Figure 3 45: Class 2 Device Recall, Boston Scientific 106
  • Figure 3 46: Class 1 Device Recall Boston Scientific 106
  • Figure 3 47: Class 2 Device Recall Boston Scientific Imager II Angiographic Catheter 107
  • Figure 3 48: Class 2 Device Recall IMAGER II Angiographic Catheters 107
  • Figure 3 49: Class 2 Device Recall Guider Softip XF 107
  • Figure 3 50: Class 1 Device Recall Boston Scientific 108
  • Figure 3 51: Class 2 Device Recall Zurpaz(TM) MEDIUM CURL, ASYMMETRIC CURVE, Steerable Sheath 108
  • Figure 3 52: Class 1 Device Recall Chariot" Guiding Sheath 108
  • Figure 3 53: Device Recall AngioJet Ultra 5000 A Console, Boston Scientific 109
  • Figure 3 54: Class 2 Device Recall AngioJet Thrombectomy Set, Boston Scientific 109
  • Figure 3 55: Class 2 Device Recall Cardinal Health 110
  • Figure 3 56: Class 2 Device Recall ViperWire Advance with Flextip Peripheral Atherectomy Guide Wire, Cardiovascular Systems Inc 111
  • Figure 3 57: Class 2 Device Recall ViperWire Advance with Flextip Peripheral Atherectomy Guide Wire, Cardiovascular Systems Inc 111
  • Figure 3 58: Class 2 Device Recall DIAMONDBACK 360 Peripheral Orbital Atherectomy System, Cardiovascular Systems Inc 111
  • Figure 3 59: Class 2 Device Recall ViperWire Advance peripheral guide wire, Cardiovascular Systems Inc 112
  • Figure 3 60: Class 1 Device Recall Diamondback 360 Peripheral Orbital Atherectomy System 112
  • Figure 3 61: Class 2 Device Recall SlipCath Beacon Tip Catheter 113
  • Figure 3 62: Class 2 Device Recall CheckFlo Performer Introducer Set 113
  • Figure 3 63: Class 2 Device Recall Micropuncture CheckFlo Performer Introducer Set 113
  • Figure 3 64: Class 2 Device Recall CheckFlo Introducer HausdorfLock Atrial 114
  • Figure 3 65: Class 3 Device Recall Gunther Tulip Vena Cava Filter Set 114
  • Figure 3 66: Class 3 Device Recall Cook Celect Platinum Vena Cava Filter Set 114
  • Figure 3 67: Class 2 Device Recall Cook Medical 115
  • Figure 3 68: Class 2 Device Recall Zenith Alpha Abdominal Endovascular Graft 115
  • Figure 3 69: Class 1 Device Recall Zenith Alpha Thoracic Endovascular Graft 115
  • Figure 3 70: Class 3 Device Recall Cordis Vista Brite Tip AdroitTM Guiding Catheter 116
  • Figure 3 71: Class 2 Device Recall POWERFLEX PRO Percutaneous Transluminal Angioplasty (PTA) Catheter 116
  • Figure 3 72: Class 1 Device Recall OptEase Vena Cava Filter, Cordis 116
  • Figure 3 73: Class 2 Device Recall Cordis S.M.A.R.T. Flex Vascular Stent System 117
  • Figure 3 74: Class 2 Device Recall Transhepatic Biliary Stent System 117
  • Figure 3 75: Class 1 Device Recall ENDOLOGIX AFX2 Bifurcated Endograft System 118
  • Figure 3 76: Class 1 Device Recall ENDOLOGIX AFX/AFX2, Proximal (Aortic) Extension Endograft 118
  • Figure 3 77: Class 1 Device Recall ENDOLOGIX AFX Endovascular AAA System 118
  • Figure 3 78: Class 1 Device Recall ENDOLOGIX AFX/AFX2, Limb (Iliac) Extension Endograft 118
  • Figure 3 79: Class 2 Device Recall AFX Endovascular AAA System, Endologix 119
  • Figure 3 80: Class 1 Device Recall IntraClude IntraAortic Occlusion Device 120
  • Figure 3 81: Class 2 Device Recall IntraClude(TM) IntraAortic Occlusion Device 120
  • Figure 3 82: Class 2 Device Recall Edwards Lifesciences IntraClude IntraAortic Occlusion Device 120
  • Figure 3 83: Class 2 Device Recall Corkscrew Catheter 120
  • Figure 3 84: Class 1 Device Recall CS100 IntraAortic Balloon Pump 121
  • Figure 3 85: Class 1 Device Recall Cardiosave Hybrid IntraAortic Balloon Pump 121
  • Figure 3 86: Class 1 Device Recall Cardiosave Hybrid IABP 121
  • Figure 3 87: Class 2 Device Recall Protege Rx Tapered Carotid Stent System, Eve Inc. 122
  • Figure 3 88: Class 1 Device Recall Covidien 122
  • Figure 3 89: Class 2 Device Recall PowerCross .018 OTW PTA Dilation Catheter, Medtronic 123
  • Figure 3 90: Class 2 Device Recall Ev3, Inc. (Medtronic) 123
  • Figure 3 91: Class 2 Device Recall Amphirion Deep OTW PTA Balloon Catheter, Medtronic 123
  • Figure 3 92: lass 2 Device Recall EV3 EverFiex" Selfexpanding Peripheral Stent System, Ev3 Inc. 124
  • Figure 3 93: Class 2 Device Recall Medtronic Aptus™ HeliFX™ Thoracic EndoAnchor™ System HeliFX Guide 42 mm, Medtronic 124
  • Figure 3 94: Class 2 Device Recall Endurant / Endurant II 23mm and 25mm Bifurcated Stent Graft Systems, Medtronic 124
  • Figure 3 95: Class 2 Device Recall FIBERNET Embolic Protection System, Medtronic 125
  • Figure 3 96: Class 2 Device Recall Spectranetics TurboElite Laser Atherectomy Catheters, Spectranetics 126
  • Figure 3 97: Class 2 Device Recall Turbo Elite Atherectomy Catheter, Spectranetics 126
  • Figure 3 98: Class 2 Device Recall TurboPower, Spectranetics 126
  • Figure 3 99: Class 1 Device Recall Bridge Balloon Catheter 127
  • Figure 3 100: Class 1 Device Recall Bridge Balloon 127
  • Figure 3 101: Class 2 Device Recall Shockwave Medical Peripheral Intravascular Lithotripsy (IVL) System 128
  • Figure 3 102: Class 2 Device Recall PINNACLE Introducer Sheath, Terumo 129
  • Figure 3 103: Class 1 Device Recall SOLOPATH Balloon Expandable TransFemoral System 129
  • Figure 3 104: Class 2 Device Recall DIAMONDBACK 360 Peripheral Orbital Atherectomy System 130
  • Figure 3 105: Class 1 Device Recall 7F Prelude Short Sheath Introducer, Merit 130
  • Figure 3 106: Class 2 Device Recall USE PTA 0.014 RX Catheter, Us Endovascular 130
  • Figure 3 107: Class 2 Device Recall Balloon Catheter, EXP Pharmaceutical Services Corp 131
  • Figure 3 108: Class 2 Device Recall IVUS Catheter, Volcano 131
  • Figure 3 109: Class 1 Device Recall Ovation Prime Abdominal Stent Graft System, TriVascular 131
  • Figure 3 110: Class 2 Device Recall Ovation Prime Abdominal Stent Graft System, TriVascular 132
  • Figure 3 111: Class 2 Device Recall MynxGrip Vascular Closure Device 132
  • Figure 3 112: Class 2 Device Recall Vascular closure device, EXP Pharmaceutical (OEM) 132
  • Figure 3 113: A Superiority Trial of the SUPERA Peripheral Stent System in Patients With Femoro-popliteal Artery Disease 133
  • Figure 3 114: Stella Supera Siberia 133
  • Figure 3 115: A Superiority Trial of the SUPERA Peripheral Stent System in Patients With Femoro-popliteal Artery Disease 134
  • Figure 3 116: Absolute Pro® MOMENTUM™ (MOMENTUM) 134
  • Figure 3 117: Comparison of the SUpera® PERipheral System in the Superficial Femoral Artery (SUPERB) 135
  • Figure 3 118: Trial to Evaluate the Safety & Efficacy of the Omnilink Elite™ Peripheral Balloon-Expandable Stent System in Subjects With Atherosclerotic de Novo or Restenotic Lesions in the Native Common Iliac Artery and/or Native External Iliac Artery (MOBILITY OE) 135
  • Figure 3 119: Trial to Evaluate the Safety & Efficacy of the Absolute Pro™ Peripheral Self-Expanding Stent System in Subjects With Atherosclerotic de Novo or Restenotic Lesions in the Native Common Iliac Artery and/or Native External Iliac Artery. (MOBILITY AP) 136
  • Figure 3 120: ESPRIT I: A Clinical Evaluation of the Abbott Vascular ESPRIT BVS (Bioresorbable Vascular Scaffold) System 136
  • Figure 3 121: Clinical Post Market Clinical Follow-up (PMCF) on Peripheral Arteries Treated With SeQuent® Please Over The Wire (OTW) 137
  • Figure 3 122: "All Comers" Post Market Clinical Follow-up (PMCF) With Multi-LOC for flOw liMiting Outcomes (LOCOMOTIVE Extended) 137
  • Figure 3 123: Safety and Effectiveness of Jetstream Atherectomy System (J-SUPREME II) 138
  • Figure 3 124: Safety and Effectiveness of Jetstream Atherectomy System (J-SUPREME) 138
  • Figure 3 125: The Jetstream (JET) Post-market Registry (JET) 139
  • Figure 3 126: RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty (RANGER II SFA) 139
  • Figure 3 127: Compare I Pilot Study for the Treatment of Subjects With Symptomatic Femoropopliteal Artery Disease 140
  • Figure 3 128: An Efficacy and Safety Study to Evaluate Ranger DEB 140
  • Figure 3 129: Trial Comparing ELUVIA Versus Bare Metal Stent in Treatment of Superficial Femoral and/or Proximal Popliteal Artery 141
  • Figure 3 130: A Real World Evaluation of the ELUVIA Stent in Subjects With Lesions Located in the Femoropopliteal Arteries (REGAL) 141
  • Figure 3 131: Peripheral Registry of Endovascular Clinical Outcomes "The PRIME Registry" (PRIME) 142
  • Figure 3 132: VIRTUS: An Evaluation of the Vici™ Venous Stent System in Patients With Chronic Iliofemoral Venous Outflow Obstruction (VIRTUS) 142
  • Figure 3 133: Real World Registry Assessing the Clinical Use of the Bard UltraScore Forced Focus PTA Balloon 143
  • Figure 3 134: Lutonix Drug Coated Balloon for Treatment of Femoropopliteal Arteries in United States Females (CONFIRM) 143
  • Figure 3 135: Real-World Registry Assessing the Clinical Use of the Lutonix 035 Drug Coated Balloon Catheter (SAFE-DCB) 144
  • Figure 3 136: Registry Investigating the Clinical Use and Safety of the Lutonix Drug Coated Balloon 144
  • Figure 3 137: Korean Post-market Registry Assessing the Clinical Use and Safety of the Lutonix DCB 145
  • Figure 3 138: BARD® The VENOVO™ Venous Stent Study for Treatment of Iliofemoral Occlusive Disease (VERNACULAR) 145
  • Figure 3 139: Real World Registry Assessing the Clinical Use of the Bard UltraScore Forced Focus PTA Balloon 146
  • Figure 3 140: Peripheral Registry of Endovascular Clinical Outcomes "The PRIME Registry" (PRIME) 146
  • Figure 3 141: The Safety and Efficacy of an Extravascular, Water-Soluble Sealant 147
  • Figure 3 142: Zilver® PTX® V Clinical Study 148
  • Figure 3 143: Zilver Flex Post-Market Study in Japan 148
  • Figure 3 144: Zilver PTX Post-Market Study in Japan 149
  • Figure 3 145: Zilver® PTX® in China 149
  • Figure 3 146: Predicting the Safety and Effectiveness of Inferior Vena Cava Filters (PRESERVE) 150
  • Figure 3 147: Paclitaxel-coated Peripheral Stents Used in the Treatment of Femoropopliteal Stenoses (XPEDITE) 150
  • Figure 3 148: FORMAT Clinical Study 151
  • Figure 3 149: VIVO Clinical Study 151
  • Figure 3 150: Study of Drug Eluting Peripheral Vascular Stent System in Superficial Femoral Artery Stenosis and /or Occlusion 152
  • Figure 3 151: Evaluation of Safety and Efficacy of the FlexStent® Femoropopliteal Self-Expanding Stent System (OPEN) 152
  • Figure 3 152: JET-RANGER Trial - JETStream Atherectomy With Adjunctive Paclitaxel-Coated Balloon Angioplasty vs Plain Old Balloon Angioplasty Followed by Paclitaxel-Coated Balloon 153
  • Figure 3 153: DiRectional AthErectomy + Drug CoAted BaLloon to Treat Long, CalcifIed FemoropopliTeal ArterY Lesions (REALITY) 153
  • Figure 3 154: A Trial to Evaluate the Safety and Efficacy of the Passeo-18 Lux Drug-coated Balloon of Biotronik in the Treatment of the Femoropopliteal Artery Compared to the Medtronic IN.PACT Admiral Drug-coated Balloon. (BIOPACT-RCT) 154
  • Figure 3 155: Prospective Study for the Treatment of Atherosclerotic Lesions in the Superficial Femoral and/or Popliteal Arteries Using the FLEX Scoring Catheter Plus DCB (FORTEZ) 154
  • Figure 3 156: IN.PACT BTK Randomized Study to Assess Safety and Efficacy of IN.PACT 014 vs. PTA 155
  • Figure 3 157: IN.PACT Global Clinical Study 155
  • Figure 3 158: Compare I Pilot Study for the Treatment of Subjects With Symptomatic Femoropopliteal Artery Disease 156
  • Figure 3 159: DiRectional AthErectomy + Drug CoAted BaLloon to Treat Long, CalcifIed FemoropopliTeal ArterY Lesions (REALITY) 156
  • Figure 3 160: Comparison of Angioplasty/Drug Coated Balloon/Laser + Drug Coated Balloon for Femoropopliteal Artery In-stent Restenosis (INTACT) 157
  • Figure 3 161: Korean Multicenter Prospective Registry of In.PACT DEB for Isolated Popliteal Artery Disease (K-POP Study) 157
  • Figure 3 162: In.Pact Flexion, Investigating the Performance of the In.Pact Admiral DEB for Popliteal Lesions (INPCTFLEXION) 158
  • Figure 3 163: IN.PACT Admiral Drug-Coated Balloon vs. Standard Balloon Angioplasty for the Treatment of Superficial Femoral Artery (SFA) and Proximal Popliteal Artery (PPA) (INPACT SFA II) 158
  • Figure 3 164: Study of IN.PACT Amphirion™ Drug Eluting Balloon vs. Standard PTA for the Treatment of Below the Knee Critical Limb Ischemia (INPACT-DEEP) 159
  • Figure 3 165: Randomized Trial of IN.PACT Admiral® Drug Coated Balloon vs Standard PTA for the Treatment of SFA and Proximal Popliteal Arterial Disease (INPACT SFA I) 159
  • Figure 3 166: The IN.PACT SFA Clinical Study for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery and/or Proximal Popliteal Artery Using the IN.PACT Admiral™ Drug-Eluting Balloon in a Chinese Patient Population 160
  • Figure 3 167: EverFlex Post Approval Study (DURABILITY PAS) 160
  • Figure 3 168: Peripheral Registry of Endovascular Clinical Outcomes "The PRIME Registry" (PRIME) 161
  • Figure 3 169: The Merit WRAPSODY™ Endovascular Stent Graft for Treatment of Iliac Artery Occlusive Disease 162
  • Figure 3 170: Radial accEss for nAvigation to Your CHosen Lesion for Peripheral Vascular Intervention: REACH PVI (REACH PVI) 163
  • Figure 3 171: DiRectional AthErectomy + Drug CoAted BaLloon to Treat Long, CalcifIed FemoropopliTeal ArterY Lesions (REALITY) 163
  • Figure 3 172: ILLUMENATE Below-The-Knee (BTK) Arteries: a Post Market Clinical Study (BTK PMS) 164
  • Figure 3 173: TurboPower + DCB Treatment of Femoropopliteal De Novo/ Restenotic and In-Stent Restenosis Lesions 164
  • Figure 3 174: ILLUMENATE Pivotal Post-Approval Study (PAS) 165
  • Figure 3 175: Pivotal Trial of a Novel Paclitaxel-Coated Percutaneous Angioplasty Balloon (ILLUMENATE) 165
  • Figure 3 176: Comparison of Angioplasty/Drug Coated Balloon/Laser + Drug Coated Balloon for Femoropopliteal Artery In-stent Restenosis (INTACT) 166
  • Figure 3 177: Global Study of a Drug-coated Balloon to Treat Obstructive SFA and/or Popliteal Lesions (ILLUMENATE) 166
  • Figure 3 178: An Evaluation of a Clinical Algorithm With Turbo-Power Following Treatment of Specific Morphologies (REX) 167
  • Figure 3 179: Shockwave Medical Peripheral Lithoplasty System Study for PAD (Disrupt PAD III) 168
  • Figure 3 180: Safety and Efficacy of the SurVeil™ Drug-Coated Balloon (TRANSCEND) 169
  • Figure 3 181: Safety and Feasibility of SurModics SurVeil (TM) Drug Coated Balloon (PREVEIL) 169
  • Figure 3 182: Treatment of Patients With Lesions in the Superficial Femoral or Popliteal Arteries Using Kanshas Drug Coated Balloon (KANSHAS1) 170
  • Figure 3 183: Misago® RX Self-Expanding Peripheral Stent 170
  • Figure 3 184: In-Stent Restenosis Post-Approval Study 171
  • Figure 3 185: Evaluation of the GORE TIGRIS Vascular Stent (TIGRIS) 171
  • Figure 3 186: A Study of the Gore VIABAHN BX for Treatment of Occlusive Disease in the Iliac Arteries. (VBXFLEX) 172
  • Figure 3 187: Multi-center Study for Stent Graft System for Peripheral Artery (VJH 11-01) 172
  • Figure 3 188: Post-Market Registry of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis Implanted in Peripheral Vessels (EXPAND) 173
  • Figure 3 189: " Endarterectomy Combined With Optimal Medical Therapy (OMT) vs OMT Alone in Patients With Asymptomatic Severe Atherosclerotic Carotid Artery Stenosis at Higher-than-average Risk of Ipsilateral Stroke " (ACTRIS) 174
  • Figure 3 190: Carotid Endarterectomy and Carotid Artery Stenting in Brazil 174
  • Figure 3 191: Remote Endarterectomy vs Remote Endarterectomy + Drug Coated Balloon (DCB) Angioplasty in Patients With the Femoral Artery Occlusive Disease 175
  • Figure 3 192: Arteriovenous Fistulae: Drug-eluting Balloon Angioplasty (FAVABED) 175
  • Figure 3 193: BIOLUX P-III BENELUX All-Comers Registry 176
  • Figure 3 194: BIOLUX P-III SPAIN All-Comers Registry 176
  • Figure 3 195: Drug Eluting Balloon for Early Fistula Failure Trial (DEBEFF) 176
  • Figure 3 196: Drug-Eluting Balloon in Arteriovenous Graft 177
  • Figure 3 197: Atherectomy and Drug-Coated Balloon Angioplasty in Treatment of Long Infrapopliteal Lesions (ADCAT) 177
  • Figure 3 198: Drug-Coated Chocolate PTA Balloon in Patients With Peripheral Arterial Disease - The ENDURE Trial (ENDURE) 177
  • Figure 3 199: AcoArt Ⅱ/ BTK China: Drug-eluting Balloon for Below-The-Knee Angioplasty Evaluation in China 178
  • Figure 3 200: AcoArt Ⅱ/ BTK China: Drug-eluting Balloon for Below-The-Knee Angioplasty Evaluation in China 178
  • Figure 3 201: Drug-eluting Balloon vs. Conventional Balloon in the Treatment of (re)Stenosis - a Randomized Prospective Study (DRECOREST1) 179
  • Figure 3 202: Stella Supera Siberia 179
  • Figure 3 203: Study to Determine the Performance of the Astron and Pulsar-18 Stents in Europe (BIOFLEX-I EU) 180
  • Figure 3 204: Clinical Study of Passeo-18 Lux Balloon Catheter for the Treatment of Atherosclerotic Lesions(BIOLUX-P IV CHINA) 180
  • Figure 3 205: Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents (BIOFLEX-I) 180
  • Figure 3 206: Evaluation of Safety and Efficacy of the FlexStent® Femoropopliteal Self-Expanding Stent System (OPEN) 181
  • Figure 3 207: Remedy, Biodegradable Peripheral Stent Registry 181
  • Figure 3 208: BIOLUX P-III All-Comers Passeo-18 Lux Registry 182
  • Figure 3 209: BIOTRONIK 4French for AMBulatory Peripheral Intervention (BIO4AMB) 182
  • Figure 4 1: Peripheral Vascular Device Market by Segment, U.S., 2016 - 2026 (US$M) (1 of 3) 186
  • Figure 4 2: Peripheral Vascular Device Market by Segment, U.S., 2016 - 2026 (US$M) (2 of 3) 187
  • Figure 4 3: Peripheral Vascular Device Market by Segment, U.S., 2016 - 2026 (US$M) (3 of 3) 188
  • Figure 4 4: Peripheral Vascular Device Market Growth by Segment, U.S., 2016 - 2026 (1 of 3) 193
  • Figure 4 5: Peripheral Vascular Device Market Growth by Segment, U.S., 2016 - 2026 (2 of 3) 194
  • Figure 4 6: Peripheral Vascular Device Market Growth by Segment, U.S., 2016 - 2026 (3 of 3) 195
  • Figure 4 7: Drivers and Limiters, Peripheral Vascular Device Market, U.S., 2019 204
  • Figure 4 8: Leading Competitors, Peripheral Vascular Device Market, U.S., 2019 (1 of 3) 214
  • Figure 4 9: Leading Competitors, Peripheral Vascular Device Market, U.S., 2019 (2 of 3) 215
  • Figure 4 10: Leading Competitors, Peripheral Vascular Device Market, U.S., 2019 (3 of 3) 216
  • Figure 4 11: SWOT Analysis, Abbott 234
  • Figure 4 12: SWOT Analysis, B. Braun 235
  • Figure 4 13: SWOT Analysis, Boston Scientific 236

For a full Table of Contents, please contact iData

目次
Product Code: iDATA_USPV20_MS

The U.S. peripheral vascular device market was valued at $7.1 billion in 2019. This is expected to increase over the forecast period at a CAGR of 5.6% to reach $10.4 billion.

One of the greatest limitations in this market is the pricing pressure that is occurring within the office-based lab (OBL) setting. Although these clinics have led to a significant increase in efficiency, reducing the average time for patients to be within a hospital, these settings are also incredibly price sensitive. It is typical that there is a 30% discount on devices sold to an OBL, relative to a hospital.

The release of the paclitaxel meta-analysis by Katsanos in late 2018 raised serious concern about the late mortality of drug-coated balloons (DCB) and drug-eluting stents (DES). At the start of 2019, the FDA announced that they would reexamine the safety of paclitaxel products in the peripheries. A large movement occurred shortly after, away from paclitaxel devices and towards more traditional devices. Although the FDA released a statement in August 2019 stating that they were not able to identify a late-mortality signal caused by paclitaxel use in the peripheries, hesitancy about the use of these devices remain.

The full report suite on the U.S. market for peripheral vascular devices includes peripheral vascular stents, venous stents, percutaneous transluminal angioplasty (PTA) balloon catheters, drug-coated balloons (DCBs), atherectomy devices, intravascular lithotripsy, chronic total occlusion (CTO) devices, surgical grafts, stent grafts, embolic protection devices (EPDs), peripheral thrombus management devices, inferior vena cava filters (IVCFs) and retrieval devices, carotid shunts, transcarotid arterial revascularization (TCAR) flow reversal systems and stents, diagnostic and interventional catheters, diagnostic and interventional guidewires, introducer sheaths, vascular closure devices (VCDs), transcatheter embolization devices and peripheral IVUS catheters. Many of these devices can be used for treating either coronary arterial disease or peripheral arterial disease (PAD). However, only devices used for peripheral procedures are included in this report.

TABLE OF CONTENTS

TABLE OF CONTENTS

LIST OF FIGURES

LIST OF CHARTS

EXECUTIVE SUMMARY

U.S. PERIPHERAL VASCULAR DEVICE MARKET OVERVIEW

COMPETITIVE ANALYSIS

MARKET TRENDS

MARKET DEVELOPMENTS

PROCEDURE NUMBERS

PROCEDURE CODES INVESTIGATED

MARKETS INCLUDED

KEY REPORT UPDATES

VERSION HISTORY

RESEARCH METHODOLOGY

    • 1.1.1 Step 1: Project Initiation & Team Selection
    • 1.1.2 Step 2: Prepare Data Systems and Perform Secondary Research
    • 1.1.3 Step 3: Preparation for Interviews & Questionnaire Design
    • 1.1.4 Step 4: Performing Primary Research
    • 1.1.5 Step 5: Research Analysis: Establishing Baseline Estimates
    • 1.1.6 Step 6: Market Forecast and Analysis
    • 1.1.7 Step 7: Identify Strategic Opportunities
    • 1.1.8 Step 8: Final Review and Market Release
    • 1.1.9 Step 9: Customer Feedback and Market Monitoring

DISEASE OVERVIEW

  • 2.1 BASIC ANATOMY
  • 2.2 DISEASE TREATMENTS & DIAGNOSTICS
    • 2.2.1 Aortic Aneurysms
    • 2.2.2 Atherosclerosis
    • 2.2.3 Peripheral Arterial Disease (PAD)
    • 2.2.4 Deep Vein Thrombosis (DVT)
    • 2.2.5 Pulmonary Embolism (PE)
  • 2.3 PATIENT DEMOGRAPHICS
    • 2.3.1 Aortic Aneurysms
    • 2.3.2 Atherosclerosis
    • 2.3.3 Peripheral Arterial Disease (PAD)
    • 2.3.4 Deep Vein Thrombosis (DVT)
    • 2.3.5 Pulmonary Embolism (PE)

PRODUCT ASSESSMENT

  • 3.1 INTRODUCTION
  • 3.2 PRODUCT PORTFOLIOS
    • 3.2.1 Peripheral Vascular Stent
    • 3.2.2 Venous Stent
    • 3.2.3 Percutaneous Transluminal Angioplasty (PTA) Balloon
    • 3.2.4 Drug-Coated Balloon
    • 3.2.5 Atherectomy Device
    • 3.2.6 Chronic Total Occlusion (CTO) Device
    • 3.2.7 Intravascular Lithotripsy
    • 3.2.8 Surgical Graft
    • 3.2.9 Stent Graft
    • 3.2.10 Embolic Protection Device
    • 3.2.11 Peripheral Thrombus Management Device
    • 3.2.12 Inferior Vena Cava Filter
    • 3.2.13 Carotid Shunt
    • 3.2.14 Diagnostic and Interventional Catheters
    • 3.2.15 Diagnostic and Interventional Guidewire
    • 3.2.16 Introducer Sheath
    • 3.2.17 Vascular Closure Device (VCD)
    • 3.2.18 Transcatheter Embolization Device
    • 3.2.19 Peripheral IVUS Catheter
  • 3.3 REGULATORY ISSUES AND RECALLS
    • 3.3.1 Abbott
      • 3.3.1.1 Carotid Shunt
      • 3.3.1.2 Vascular Closure Device
    • 3.3.2 Argon Medical
      • 3.3.2.1 Introducer Sheaths
    • 3.3.3 Arrow International
      • 3.3.3.1 Introducer Sheaths
    • 3.3.4 Atrium Medical
      • 3.3.4.1 Peripheral Vascular Stent
    • 3.3.5 BD
      • 3.3.5.1 Inferior Vena Cava Filter
      • 3.3.5.2 Introducer Sheaths
      • 3.3.5.3 Stent Graft
    • 3.3.6 Boston Scientific
      • 3.3.6.1 Atherectomy Devices
      • 3.3.6.2 Diagnostic and Interventional Catheters
      • 3.3.6.3 Introducer Sheaths
      • 3.3.6.4 Peripheral Thrombus Management Devices
    • 3.3.7 Cardinal Health
      • 3.3.7.1 Vascular Closure Devices
    • 3.3.8 Cardiovascular System (C.S.I.)
      • 3.3.8.1 Atherectomy Devices
    • 3.3.9 Cook Medical
      • 3.3.9.1 Diagnostic and Interventional Catheters
      • 3.3.9.2 Introducer Sheaths
      • 3.3.9.3 Inferior Vena Cava Filters
      • 3.3.9.4 Peripheral Vascular Stents
      • 3.3.9.5 Stent Grafts
    • 3.3.10 Cordis (Cardinal Health)
      • 3.3.10.1 Diagnostic and Interventional Catheters
      • 3.3.10.2 Inferior Vena Cava Filters
      • 3.3.10.3 Peripheral Stents
    • 3.3.11 Endologix
      • 3.3.11.1 Stent Grafts
    • 3.3.12 Edwards Lifesciences
      • 3.3.12.1 Chronic Total Occlusion Devices
    • 3.3.13 Maquet
      • 3.3.13.1 PTA Balloons
    • 3.3.14 Medtronic
      • 3.3.14.1 Carotid Shunts
      • 3.3.14.2 Diagnostic and Interventional Catheters
      • 3.3.14.3 PTA Balloon Catheters
      • 3.3.14.4 Peripheral Stents
      • 3.3.14.5 Stent Grafts
      • 3.3.14.6 Transcatheter Embolization Devices
    • 3.3.15 Spectranetics (Philips)
      • 3.3.15.1 Atherectomy Devices
      • 3.3.15.2 Chronic Total Occlusion Devices
    • 3.3.16 Shockwave Medical, Inc.
      • 3.3.16.1 Intravascular Lithotripsy
    • 3.3.17 Terumo
      • 3.3.17.1 Introducer Sheaths
      • 3.3.17.2 PTA Balloon Catheters
    • 3.3.18 Other Companies
      • 3.3.18.1 Atherectomy Devices
      • 3.3.18.2 Introducer Sheaths
      • 3.3.18.3 PTA Balloon Catheters
      • 3.3.18.4 Peripheral IVUS Catheters
      • 3.3.18.5 Stent Grafts
      • 3.3.18.6 Vascular Closure Devices (VCD)
  • 3.4 CLINICAL TRIALS
    • 3.4.1 Abbott
      • 3.4.1.1 Peripheral Vascular Stent
      • 3.4.1.2 Other Peripheral Vascular Related Studies
    • 3.4.2 B. Braun
      • 3.4.2.1 Diagnostic and Interventional Catheters
      • 3.4.2.2 Peripheral Vascular Stent
    • 3.4.3 Boston Scientific
      • 3.4.3.1 Atherectomy Devices
      • 3.4.3.2 Drug-Coated Balloons
      • 3.4.3.3 Peripheral Vascular Stents
      • 3.4.3.4 Other Peripheral Vascular Related Studies
      • 3.4.3.5 Venous Stents
    • 3.4.4 C.R. Bard (BD)
      • 3.4.4.1 Diagnostic and Interventional Catheters
      • 3.4.4.2 Drug-Coated Balloons
      • 3.4.4.3 Venous Stents
      • 3.4.4.4 Other Peripheral Vascular Related Studies
    • 3.4.5 Cardinal Health
      • 3.4.5.1 Other Peripheral Vascular Related Studies
    • 3.4.6 Cook Medical
      • 3.4.6.1 Drug-Eluting Stents
      • 3.4.6.2 Inferior Vena Cava Filters
      • 3.4.6.3 Peripheral Vascular Stents
      • 3.4.6.4 Venous Stents
    • 3.4.7 Cordis (Cardinal Health)
      • 3.4.7.1 Peripheral Vascular Stents
    • 3.4.8 Medtronic
      • 3.4.8.1 Atherectomy Devices
      • 3.4.8.2 Drug-Coated Balloons
      • 3.4.8.3 Other Peripheral Vascular Related Studies
    • 3.4.9 Merit Medical
      • 3.4.9.1 Stent Grafts
    • 3.4.10 Philips/Spectranetics
      • 3.4.10.1 Atherectomy Devices
      • 3.4.10.2 Peripheral IVUS Catheters
      • 3.4.10.3 Spectranetics
      • 3.4.10.3.1 Drug-Coated Balloons
      • 3.4.10.3.2 Atherectomy Devices
    • 3.4.11 Shockwave Medical, Inc.
      • 3.4.11.1 Lithoplasty System
    • 3.4.12 Surmodics
      • 3.4.12.1 Drug-Coated Balloons
    • 3.4.13 Terumo
      • 3.4.13.1 Drug-Coated Balloons
      • 3.4.13.2 Peripheral Vascular Stents
    • 3.4.14 W.L. Gore
      • 3.4.14.1 Peripheral Vascular Stents
      • 3.4.14.2 Stent Grafts
      • 3.4.14.3 Expandable Balloons
    • 3.4.15 Other Companies
      • 3.4.15.1 Carotid Shunt / Endarterectomy
      • 3.4.15.2 Drug-Coated Balloons
      • 3.4.15.3 Peripheral Vascular Stents
      • 3.4.15.4 Other Peripheral Vascular Related Studies

U.S. PERIPHERAL VASCULAR DEVICE MARKET OVERVIEW

  • 4.1 INTRODUCTION
    • 4.1.1 Atherosclerosis
    • 4.1.2 Peripheral Arterial Disease (PAD)
  • 4.2 MARKET OVERVIEW
  • 4.3 TREND ANALYSIS BY SEGMENT
  • 4.4 DRIVERS AND LIMITERS
    • 4.4.1 Market Drivers
    • 4.4.2 Market Limiters
  • 4.5 COMPETITIVE MARKET SHARE ANALYSIS
  • 4.6 MERGERS AND ACQUISITIONS
  • 4.7 COMPANY PROFILES
    • 4.7.1 Abbott
    • 4.7.2 Becton Dickinson (BD)
    • 4.7.3 Boston Scientific
    • 4.7.4 Cardinal Health
      • 4.7.4.1 Cordis (Cardinal Health)
    • 4.7.5 Cook Medical
    • 4.7.6 Maquet
    • 4.7.7 Medtronic
    • 4.7.8 Teleflex
    • 4.7.9 Terumo Interventional System (TIS)
    • 4.7.10 W.L. Gore
  • 4.8 SWOT ANALYSIS
    • 4.8.1 Abbott
    • 4.8.2 B. Braun
    • 4.8.3 Boston Scientific
    • 4.8.4 BD
    • 4.8.5 Cardinal Health
    • 4.8.6 Cook Medical
    • 4.8.7 Integra Lifesciences
    • 4.8.8 Maquet
    • 4.8.9 Medtronic
    • 4.8.10 Merit Medical
    • 4.8.11 Phillips
    • 4.8.12 Teleflex
    • 4.8.13 Terumo
    • 4.8.14 W.L. Gore

PROCEDURE NUMBERS

  • 5.1 INTRODUCTION
  • 5.2 PROCEDURES
    • 5.2.1 Total Peripheral Vascular Procedures
    • 5.2.2 Total Peripheral Vascular Procedures by Device Type, Indication, Intervention & Care Setting
      • 5.2.2.1 Above-the-Knee Procedures
      • 5.2.2.1.1 Above-the-Knee Stent Procedures
      • 5.2.2.1.2 Above-the-Knee POBA Procedures by Care Setting
      • 5.2.2.1.3 Above-the-Knee DCB Procedures by Care Setting
      • 5.2.2.1.4 Above-the-Knee Atherectomy without Stent Procedures by Care Setting
      • 5.2.2.1.5 Above-the-Knee Atherectomy with Stent Procedures by Care Setting
      • 5.2.2.2 Below-the-Knee Procedures
      • 5.2.2.2.1 Below-the-Knee Stent Procedures by Device Type
      • 5.2.2.2.2 Below-the-Knee Stent Procedures by Care Setting
      • 5.2.2.2.3 Below-the-Knee POBA Procedures by Care Setting
      • 5.2.2.2.4 Below-the-Knee DCB Procedures by Care Setting
      • 5.2.2.2.5 Below-the-Knee Atherectomy without Stent Procedures by Care Setting
      • 5.2.2.2.6 Below-the-Knee Atherectomy with Stent Procedures by Care Setting
      • 5.2.2.3 Iliac Procedures
      • 5.2.2.3.1 Iliac Stent Procedures by Device Type
      • 5.2.2.3.2 Iliac Stent Procedures by Care Setting
      • 5.2.2.3.3 Iliac POBA Procedures by Care Setting
      • 5.2.2.4 AV Access Procedures
      • 5.2.2.4.1 AV Access Covered Stent Procedures by Care Setting
      • 5.2.2.4.2 AV Access POBA Procedures by Care Setting
      • 5.2.2.4.3 AV Access DCB Procedures by Care Setting
      • 5.2.2.5 Renal Procedures
      • 5.2.2.6 Carotid Procedures
    • 5.2.3 Peripheral Vascular Stent Procedures
      • 5.2.3.1 Peripheral Arterial Stent Procedures by Stent Type
      • 5.2.3.1.1 Bare-Metal Stent Procedures
      • 5.2.3.1.2 Covered Stent Procedures
      • 5.2.3.1.3 Drug-Eluting Stent Procedures
    • 5.2.4 Peripheral Venous Stent
    • 5.2.5 PTA Balloon Catheter Procedures
    • 5.2.6 Drug-Coated Balloon Procedures
      • 5.2.6.1 Drug-Coated Balloon Procedures by Indication
    • 5.2.7 Atherectomy Procedures
      • 5.2.7.1 Atherectomy Procedures by Device Type
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.